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Abstract
There is a dearth of guidance on the management of prosthetic joint infections (PJIs), in particular 
because of the lack of high-quality evidence for optimal antibiotics. Thus, we designed a nine-
question survey of current practices and preferences among members of the Emerging Infections 
Network, a CDC-sponsored network of infectious diseases physicians, which was distributed in 
May 2012. In total, 556 (47.2%) of 1178 network members responded. As first-line antibiotic 
choice for MSSA PJI, 59% of responders indicated oxacillin/nafcillin, 33% cefazolin and 7% 
ceftriaxone; the commonest alternative was cefazolin (46%). For MRSA PJI, 90% preferred 
vancomycin, 7% daptomycin and 0.8% ceftaroline; the commonest alternative was daptomycin 
(65%). Antibiotic selection for coagulase-negative staphylococci varied depending on meticillin 
susceptibility. For staphylococcal PJIs with retained hardware, most providers would add 
rifampicin. Propionibacterium is usually treated with vancomycin (40%), penicillin (23%) or 
ceftriaxone (17%). Most responders thought 10–19% of all PJIs were culture-negative. Culture-
negative PJIs of the lower extremities are usually treated with a vancomycin/fluoroquinolone 
combination, and culture-negative shoulder PJIs with vancomycin/ceftriaxone. The most cited 
criteria for selecting antibiotics were ease of administration and the safety profile. A treatment 
duration of 6–8 weeks is preferred (by 77% of responders) and is mostly guided by clinical 
response and inflammatory markers. Ninety-nine percent of responders recommend oral antibiotic 
suppression (for varying durations) in patients with retained hardware. In conclusion, there is 
considerable variation in treatment of PJIs both with identified pathogens and those with negative 
cultures. Future studies should aim to identify optimum treatment strategies.
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1. Introduction
Prosthetic joint infections (PJIs) are among the most common indications for long-term 
intravenous (i.v.) antibiotic treatment and a common reason for outpatient parenteral 
antibiotic treatment (OPAT) in the USA [1]. Due to an aging population and more joint 
arthroplasties being performed, the incidence of PJIs has increased over the past two 
decades [2]. Unlike many other infections, however, there is no reliable test of cure available 
for PJIs. The clinical response and functional status during recovery can be used to assess 
treatment response, but they are limited by subjectivity and inter-rater variability. Providers 
also commonly use relatively non-specific laboratory tests [e.g. erythrocyte sedimentation 
rate (ESR), serum C-reactive protein (CRP)] for monitoring purposes or obtain imaging 
studies, which may not be able to differentiate between ongoing infection and bone 
restructuring [3]. These limitations may explain the dearth of head-to-head comparisons of 
antibiotics or treatment strategies for PJIs [4]. As a result, infectious diseases physicians 
receive little robust guidance when making clinical decisions for these patients and are 
largely left to expert opinion [5,6]. For the same pathogen, multiple different antibiotics 
could be selected [5]. The recommended treatment duration is based on limited evidence [7]. 
Likewise, the surgical approach lacks standardisation [8].
The Infectious Diseases Society of America (IDSA) is therefore in the process of creating 
guidelines to standardise the management of PJIs. In the meantime, we wanted to understand 
better the practice patterns of infectious diseases providers regarding antibiotic treatment 
and treatment response monitoring. The Emerging Infections Network (EIN), a provider-
based sentinel network run by the IDSA (http://ein.idsociety.org/), was utilised. A survey 
was designed to address the following questions: (i) which antibiotics are most commonly 
chosen by providers in the EIN network for common PJI pathogens or culture-negative 
infections, and what criteria influence this choice; (ii) how long are i.v. antibiotics given; 
(iii) what is the prevalence of oral antibiotic use for PJI treatment; and (iv) what are the most 
frequently used elements to determine when treatment can be discontinued. In summary, we 
intended to obtain in-depth information on current practices in PJI management, in the 
absence of robust evidence or national guidelines.
2. Material and methods
The IDSA’s EIN is a provider-based, emerging infections sentinel network that was 
established through a Cooperative Agreement Program Award from the US Centers for 
Disease Control and Prevention (CDC, Atlanta, GA) [9]. It consists of physicians who 
practice adult and paediatric infectious diseases medicine, belong to either the IDSA or the 
Pediatric Infectious Diseases Society, and who have volunteered to participate in the 
network. EIN member physicians represent ca. 20% of infectious diseases subspecialists in 
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the USA certified by the American Board of Internal Medicine. For the purpose of this 
study, we focused on EIN members who manage adult patients.
The study objective was to understand better the practice patterns of infectious diseases 
specialists who treat PJIs. Survey questions were developed in collaboration between the 
EIN leadership (SEB and PP) and the Division of Infectious Diseases at Washington 
University School of Medicine (JM, MAL and HMB). A subset of EIN Executive 
Committee members and several Washington University infectious diseases physicians 
involved in the care of patients with PJIs piloted the survey. In May 2012, the survey was 
sent out in its final form to 1178 EIN members practicing in North America.
The survey consisted of introductory text and nine questions sent by electronic mail or 
facsimile; the initial mailing was followed by two subsequent reminders for non-responders, 
sent 2 weeks and 4 weeks after the original email. Survey questions addressed antibiotic 
preferences and management practices for PJIs. Antibiotic preferences focused on first, 
second and third antibiotic choices for the most common causes of PJIs [meticillin-
susceptible Staphylococcus aureus (MSSA), meticillin-resistant S. aureus (MRSA), 
meticillin-susceptible coagulase-negative staphylococci (MS-CoNS), meticillin-resistant 
CoNS (MR-CoNS) and Propionibacterium spp.]. Also, preferred single-drug or combination 
regimens for culture-negative infections were elicited for three commonly involved joints 
(hip, knee and shoulder). One question focused on the addition of rifampicin to the main 
antibiotic for hardware-associated infections. Participants were asked to rank important 
criteria for choosing a particular antibiotic (ranking a selection of six criteria in order of 
relevance, with 1 being the most relevant; the average was inverted with 1/x to yield a higher 
number the more relevant the criterion was). The preferred duration of antibiotic treatment, 
criteria for defining success, and when antibiotics could be discontinued were also 
determined. Denominators for some questions varied because not all EIN members 
responded to all questions. Differences in frequencies were analysed for statistical 
significance using χ2 tests, Student’s t-test and Mann–Whitney U-test as appropriate. A P-
value of <0.05 was considered significant. The statistical package SPSS v.18 (SPSS Inc., 
Chicago, IL) was used for analyses.
3. Results
3.1. Response rate and demographics of responding physicians
Overall, 556 (47.2%) of 1178 participating physicians responded to the survey. A total of 73 
EIN members who have never responded to a survey during their membership were 
excluded from the denominator, giving a response rate of 50.3% (i.e. 556/1105). Moreover, 
85 members responded by email that they do not see patients with PJIs; these individuals 
were not included in further analyses, which resulted in a cohort of 471 respondents. Not all 
respondents answered all questions and therefore denominators for individual questions 
varied.
The number of respondents per geographic division of the USA, as defined by the US 
Census Bureau (http://www.census.gov/geo/www/us_regdiv.pdf), was calculated. Providers 
from all geographic regions were included, with the largest numbers stemming from the 
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South Atlantic (93/556; 17%), Pacific (89/556; 16%), the Mid-Atlantic (84/556; 15%) and 
the East North Central region (81/556; 15%). Eight providers (1%) responded from Canada. 
In terms of professional experience, the largest responding group was 160 physicians with 
≥25 years of experience (i.e. 59% of 273 in this category). With regard to employment, 188 
(34%) were employed by a university hospital or medical school, 177 (32%) were in private 
practice, 153 (28%) worked in a hospital and 38 (7%) were employed by the Veteran 
Administration (VA), military or a state-directed institution. The hospitals where patients are 
seen were university hospitals (181; 33%), non-university teaching hospitals (166; 30%), 
community hospitals (147; 26%), VA or military hospitals (34; 6%) or others. Data came 
from small hospitals with <200 beds (10%), midsize hospitals with 200–600 beds (66%) and 
large hospitals with >600 beds (24%).
Survey respondents were significantly more likely than non-respondents to have ≥15 years 
of infectious diseases experience (P < 0.0001).
3.2. Antibiotic choices for known pathogens
For PJI due to MSSA, 59% (277/471) of responders indicated oxacillin/nafcillin as their 
first-line antibiotic choice, 33% (154/471) preferred cefazolin and 7% (34/471) ceftriaxone 
(Fig. 1). The most frequently selected second choice was cefazolin (46%). Ceftriaxone was 
cited as second choice for 13% and third choice for 20%. Daptomycin played a minor role, 
with 0.2% indicating it as first choice and 2% and 5% as second and third choice, 
respectively.
For MRSA PJIs, 90% (426/471) preferred vancomycin, 7% (31/471) daptomycin and 0.8% 
(4/471) ceftaroline; the most frequently selected second choice was daptomycin (65%) and 
the third linezolid (27%) (Fig. 2). Ceftaroline, recently approved by the US Food and Drug 
Administration (FDA) (for pneumonia and skin/skin-structure infections), was the third 
choice for 14% of respondents. Telavancin was not included among treatment options for 
MRSA since it was not commercially available at the time of this survey.
Choices for CoNS varied depending on meticillin susceptibility. The preferences for MR-
CoNS followed very closely those for MRSA (Fig. 3). For MS-CoNS (Fig. 4), 51% 
(239/470) and 24% (113/470) selected oxacillin and cefazolin as first option, respectively. 
However, another 17% (80/470) of providers indicated vancomycin as first choice. 
Daptomycin was ranked more frequently as a second option for MS-CoNS than for MSSA 
infections (10% vs. 2%; P < 0.001).
If hardware is retained in staphylococcal infections, 55% (256/468) of providers would add 
rifampicin to the main antibiotic for more than one-half of their patients; 5% (23/468) would 
never use rifampicin in that setting.
Propionibacterium infections are usually treated with vancomycin (40%; 181/453), 
penicillin (23%; 106/453) or ceftriaxone (17%; 78/453) (Fig. 5). Providers gave a number of 
other antimicrobials as options, such as clindamycin, daptomycin and linezolid. The most 
frequently chosen second-line treatment was vancomycin (18%).
Marschall et al. Page 4
Int J Antimicrob Agents. Author manuscript; available in PMC 2014 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3.3. Antibiotic choices for culture-negative prosthetic joint infections
Most responders (33%) indicated that culture-negative PJIs made up 10–19% of cases; 
another 23% indicated 20–29% of PJI episodes seen in their practice were culture-negative. 
A two-drug regimen was chosen by approximately two-thirds of respondents for treatment 
of culture-negative PJIs [by 68% (313/463) of providers for knee infections, 69% (317/462) 
for hip infections and 63% (289/458) for shoulder infections]. Combinations of either 
vancomycin and ceftriaxone or vancomycin and a fluoroquinolone were most popular. The 
third most common combination was vancomycin with cefepime. Lower extremity culture-
negative PJIs are most commonly treated with a combination of vancomycin and a 
fluoroquinolone [31% (98/313) of knee PJIs and 28% (88/317) of hip PJIs]. Shoulder PJIs 
are more commonly treated with vancomycin and ceftriaxone (24%; 69/291). If a single-
drug regimen was selected for any culture-negative PJI, vancomycin was the most common 
choice (223/282; 79%). Three-drug regimens were not used frequently (see Fig. 6).
3.4. Criteria for specific antibiotic choices
The most cited criteria for selecting antibiotics were ease of administration (ranking = 0.675, 
with the maximum mean being 1) and the safety profile (0.638). Patient preference was not 
indicated as an important determinant of antibiotic choice (0.221), nor were monitoring 
requirements (0.254) (Fig. 7).
3.5. Antibiotic treatment duration and criteria for discontinuing treatment
A treatment duration of 6–8 weeks is preferred by 77% of responders and is mostly guided 
by clinical response (ranking = 0.795) and inflammatory markers (0.512); imaging has a 
minor role (0.269). Only two providers (0.4%) opted for a treatment duration of less than 4 
weeks. Switching from i.v. to oral antibiotics to complete a treatment course was not a 
commonly cited practice (73/462; 16%). For patients with PJI and retained prosthetic 
material who were given oral antibiotic suppression, providers varied in their preferred 
duration of suppression (23% would treat for months, 35% for years and 41% lifelong); very 
few providers would not recommend suppression (n = 5; 1%).
4. Discussion
With the ageing of the US population, there has been a parallel increase in total joint 
arthroplasties and subsequent PJIs. Optimum management of these PJIs, however, is 
compromised for several reasons: (i) the diagnostic work-up does not yield a causative 
pathogen in at least 7–9.5% of episodes [10]; (ii) very few head-to-head trials of different 
antibiotics for PJI have been conducted; and (iii) there is no standardised test of cure for PJI. 
We were interested in better understanding current treatment practices and antibiotic 
preferences of infectious diseases physicians who provide care to patients with PJIs. 
Considerable variation in practices was encountered.
Providers chose oxacillin/nafcillin (59%), cefazolin (33%) or ceftriaxone (7%) as first 
option for MSSA. Oxacillin, nafcillin and other anti-staphylococcal penicillins are 
considered the standard treatment for MSSA [11], and cefazolin is a reasonable alternative 
[12]. Cefazolin may have been chosen relatively frequently because its dosing schedule is 
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more compatible with OPAT than that of oxacillin/nafcillin. Another possibility is that 
providers favour cefazolin in settings of possible penicillin allergy. Although comparative 
data are lacking for PJIs, studies on the effectiveness of cefazolin for MSSA bacteraemias 
indicated that it is similar to oxacillin and better than vancomycin [13]. Ceftriaxone, dosed 
once daily, has recently been favourably compared with oxacillin for bone and joint 
infections [14] but is not frequently used among EIN members. Treatment for MRSA 
appears to be much more uniform, with 90% of providers choosing vancomycin as their 
first-line treatment option. Very little evidence supports the use of daptomycin [15]; it is, 
however, well tolerated and does not require serum levels to be measured.
With regard to CoNS, it is noteworthy that 17% of EIN members indicated vancomycin as 
first choice in meticillin-susceptible isolates, although this may be inferior to treatment with 
β-lactams and is not recommended by experts [5]. Providers were also not uniform in their 
approach to Propionibacterium infections. These skin bacteria are thought to be of low 
virulence but are considered an emerging pathogen in PJIs [16]. The standard treatment is β-
lactams (in particular penicillin and ceftriaxone), to which Propionibacterium acnes is 
almost exclusively susceptible [17]. Here, vancomycin was the predominantly selected first 
choice antibiotic; this was unexpected as vancomycin is less convenient than ceftriaxone for 
administration and may not be clinically equivalent.
Very little information is available on culture-negative PJIs, for which antibiotic exposure 
prior to the diagnostic work-up is a risk factor [18]. It is possible that these infections are 
caused by atypical pathogens that cannot be identified with traditional microbiological 
methods [19]. Other so-called culture-negative infections may in fact be inflammatory 
conditions due to prosthetic material intolerability [20], manifestations of rheumatic disease, 
gouty arthritis, or represent aseptic loosening. With regard to antibiotic management of these 
infections, there is very little guidance available in the scientific literature. It is particularly 
difficult to define treatment failure in affected patients, which complicates the design of 
future studies on optimal treatment. A multitude of treatment regimens have been used [10]. 
We found that most EIN providers preferred two-agent regimens (vancomycin and 
ceftriaxone, or vancomycin and fluoroquinolone). Given that staphylococci are the 
predominant cause of infection, it is reasonable to make vancomycin the backbone of the 
regimen; the addition of Gram-negative coverage may or may not be necessary. It is also 
noteworthy that responders estimated the percentage of culture-negative PJIs to be much 
higher than reported before [10].
In 1998, Zimmerli et al. demonstrated in a landmark paper that addition of rifampicin (to 
oral ciprofloxacin) for staphylococcal PJIs with retained hardware resulted in improved 
outcomes [21]. The underlying rationale for this study was that rifampicin penetrates fairly 
well into bacterial biofilms and that it has an effect on stationary phase bacteria, such as 
those embedded in a hardware-related biofilm. However, rifampicin has the potential for 
drug interactions and may not be a suitable choice for all patients, e.g. those on 
anticoagulation. Also, despite further data supporting the addition of rifampicin to oral 
antibiotics [22,23], there are no clinical data available on rifampicin combined with i.v. 
antibiotics [24], which is common practice in North America. In this study, we found that 
providers would give rifampicin to most of their patients with staphylococcal PJIs and 
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retained hardware; this level of acceptance of rifampicin as an adjunctive agent has not been 
documented before. This isolated finding should be interpreted cautiously as we did not 
elicit experiences with rifampicin discontinuation due to interactions or treatment outcomes 
with rifampicin-containing regimens.
There is no single test of cure for determining the treatment response in PJIs, creating a 
significant challenge for physicians. Repeat joint aspirations are occasionally done to 
monitor the treatment response but are more established as a test to rule out ongoing 
infection prior to re-implant. Therefore, clinicians often rely on surrogate markers such as 
peripheral white blood count, ESR, serum CRP [25] and, perhaps, imaging studies. By far 
the most important criterion to EIN members in this survey, however, was how patients 
responded clinically to the treatment. This endpoint is difficult to capture in a quantitative 
way and has not been included in current expert recommendations [5,6]. In addition, the 
optimum duration of medical treatment is not defined [26]. Most EIN members agreed with 
the standard of ca. 6 weeks of antibiotic treatment following surgery [27].
Another area of much controversy is whether oral antibiotic suppression is required for 
patients with PJIs managed with debridement and hardware retention and, if so, for how 
long. This approach is associated with low success rates [28] and should be reserved for 
patients with a short duration of symptoms, stable implant material, largely intact overlying 
tissue, and those who are poor candidates for removal surgery. In fact, Koeppe et al. stated 
in their systematic review of the literature that there is no clear indication for using 
suppression [29]. The optimum duration is also unclear. Nevertheless, almost all providers 
(99%) would use oral antibiotics for an extended time. The preferred duration of suppression 
varied enormously, reflecting the paucity of supporting data.
Limitations of this report include the possibility that the survey responses may not reflect the 
reality of how providers actually manage PJIs. Also, specific antibiotic choices cannot be 
linked to outcomes, which is an inherent limitation of surveys. The sample size of ca. 500 
infectious diseases physicians was large but may not be representative for the entire 
infectious diseases physician community. For example, younger providers (possibly with 
different management preferences) were less likely to respond to this survey. The findings 
should also not be generalised to other geographic regions with different PJI management 
strategies. Lastly, we focused on the medical management aspect; surgical strategies have 
been studied in a previous survey [30].
In conclusion, many preferences and practices in the care of patients with PJIs are based on 
limited evidence, which may explain the significant variation in management. The upcoming 
IDSA guidelines are highly anticipated but, given the lack of robust data, are likely to be 
largely based on expert opinion. Comparative effectiveness studies of different regimens for 
identified pathogens and for culture-negative PJIs, as well as studies of rifampicin combined 
with i.v. antibiotics, should be performed in the future.
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Fig. 1. 
Antibiotic preferences for meticillin-susceptible Staphylococcus aureus (MSSA), as a 
percentage of all responders. Oxa, oxacillin/nafcillin; Cef, cefazolin; CTX, ceftriaxone; Van, 
vancomycin; Dap, daptomycin.
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Fig. 2. 
Antibiotic preferences for meticillin-resistant Staphylococcus aureus (MRSA), as a 
percentage of all responders. Van, vancomycin; Dap, daptomycin; LZD, linezolid; CTL, 
ceftaroline.
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Fig. 3. 
Antibiotic preferences for meticillin-resistant coagulase-negative staphylococci (CoNS), as a 
percentage of all responders. Van, vancomycin; Dap, daptomycin; LZD, linezolid; CTL, 
ceftaroline.
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Fig. 4. 
Antibiotic preferences for meticillin-susceptible coagulase-negative staphylococci (CoNS), 
as a percentage of all responders. Oxa, oxacillin/nafcillin; Cef, cefazolin; Van, vancomycin; 
CTX, ceftriaxone; Dap, daptomycin; LZD, linezolid.
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Fig. 5. 
Antibiotic preferences for Propionibacterium spp., as a percentage of all responders. Van, 
vancomycin; Pen, penicillin; CTX, ceftriaxone; Clin, clindamycin; Cef, cefazolin; Dap, 
daptomycin; LZD, linezolid.
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Fig. 6. 
Preferences for combination regimens for treatment of culture-negative prosthetic joint 
infections, as a percentage of responders.
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Fig. 7. 
Most important considerations when selecting antibiotics for prosthetic joint infections 
(assuming in vitro susceptibility and equivalent efficacy). Six criteria were ranked from 1 
(most important) to 6 (least important); mean values were inverted with 1/x to yield higher 
values for more important criteria.
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